Genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer

ChEBI2011-05-11 更新2026-07-21 收录

乳腺癌新辅助化疗预测

肿瘤基因组学预后模型

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-GEOD-25066 数据链接链接失效反馈

官方服务：

资源简介：

Genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer

创建时间：

2011-05-11

Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer

乳腺癌新辅助化疗预测

肿瘤免疫生物标志物

We report the ability of a gene expression signature to predict response to neoadjuvant chemotherapy in early breast cancer, and also describe transcriptomic changes during treatment Overall design: T

NIAID Data Ecosystem70

Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab on NSABP B-40. Homo sapiens

乳腺癌新辅助化疗预测

牛基因组关联研究

"Source of Patients Patients entered into this study were from the NSABP B-40 trial in which patients were randomized to one of three chemotherapy regimens with one-half of the patients also randomize

NIAID Data Ecosystem50

Biomarker analysis of neoadjuvant Doxorubicin/Cyclophosphamide followed by Ixabepilone or Paclitaxel in early-stage breast cancer

乳腺癌新辅助化疗预测

基因表达标志物验证

A randomized, open-label, multicenter, phase II trial (NCT00455533) enrolled previously untreated women with histologically-confirmed primary invasive breast adenocarcinoma (T2–3, N0–3, M0, tumor size

NIAID Data Ecosystem50

Table_1_Baseline Mutations and Up-Regulation of PI3K-AKT Pathway Serve as Potential Indicators of Lack of Response to Neoadjuvant Chemotherapy in Stage II/III Breast Cancer.xlsx

乳腺癌新辅助化疗预测

基因生物标志物发现

BackgroundNeoadjuvant chemotherapy (NAC) has been expanded to hormone receptor (HR) positive breast cancer (BC) patients with operable disease, to increase the likelihood of breast-conserving surgery.

NIAID Data Ecosystem60

On-Treatment Biomarkers Improve Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer. On-Treatment Biomarkers Improve Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer

乳腺癌新辅助化疗预测

治疗中生物标志物发现

Background: Neoadjuvant chemotherapy is increasingly being used to preoperatively shrink breast tumours prior to surgery. This approach also provides the opportunity to study the molecular changes ass

NIAID Data Ecosystem50

Genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer

资源简介：

相关数据集